drugset / Trial / NCT00479648

A Phase 2 Study of Immunogenicity, Safety and Tolerability of CSL412 in Elderly Participants

NCT00479648

Phase 2 Completed 612 enrolled Seqirus
RandomizedParallel-groupQuadruple-blind

Summary

Current influenza vaccines have a reduced efficacy in the elderly. This study will investigate the immunogenicity, safety and tolerability of an adjuvanted influenza vaccine in elderly participants.

Timeline

Start
2007-05
Primary completion
2007-08
Completion
2007-08

Drugs

EvaluationDrugModalityDoseRoute
Subject CSL412 Vaccine
Comparator Inactivated Trivalent Influenza Vaccine Vaccine

Indications